The study focuses on adults who have a type of blood cancer called B-cell Non-Hodgkin Lymphoma that has come back after treatment or does not respond to standard therapy. The investigational medicine being tested is a laboratory‑made protein given as a subcutaneous injection, identified by the code name GSK5926371. This medication is designed to target the cancer cells directly.
The purpose of the trial is to evaluate the safety and clinical activity of the drug and to determine the appropriate dose for later studies. Participants will receive a series of injections over several weeks while doctors monitor them closely for any signs of dose limiting toxicities, adverse events or serious adverse events. Routine visits will include blood work, checks of vital signs such as blood pressure and heart rate, and an electrocardiogram (ECG) to record the heart’s electrical activity.
Additional evaluations will look at how well the cancer responds, measured by the Overall Response Rate (ORR), and will also assess how the drug behaves in the body, including its Maximum concentration (Cmax), the time it takes to reach that level (Time to Cmax (Tmax)), and the total exposure over time (Area under the curve (AUC)). These assessments help researchers understand both the effectiveness and the safety profile of the treatment.
Finland 
France 
Italy 
